ItisacknowIedgedthatintestinaImicrobiotapIaysanimportantroIeinIifeprocess.IntestinaIdysbiosisis invoIved in the pathogenesis of many diseases reIated to aImost every system of the body. Probiotics and fecaI microbiota transpIantation,which can moduIate intestinaI microbiota without severe adverse effects,has become a hot topic for disease treatment. This articIe summarized the use of intestinaI microbiota moduIation for treatment of digestive system diseases.

Extranodal natural killer/T cell lymphoma (ENKTL) is an EBV-associated and highly aggressive subtype of non-Hodgkin lymphoma. Most patients are distributed in Asia and South America, and advanced-stage patients have poor prognosis. Reports on research progress of ENKTL in the 58th American Society of Hematology Annual Meeting covered multiple respects which range from basic research to clinical prognosis and treatment: further study on pathogenesis of ENKTL is developing based on high-throughput sequence, and new prognostic index system can help to stratify patients more exactly; what's more, novel regimens make more benefits to the clinical efficacy and safety of ENKTL patients.

Chronic lymphocytic leukemia (CLL) is a chronic B-cell lymphoproliferative clonal disease with a highly heterogeneous clinical course. In recent years, with the emerging of immunochemotherapy, bcl-2 inhibitor, B-cell receptor signal transduction kinase inhibitors and the chimeric antigen receptor-T cell (CAR-T), more and more improvements were made in CLL therapy and remission. This report addressed the progress of CLL therapy in the 57th American Society of Hematology annual meeting.

Waldenstrom macroglobulinemia (WM) is a malignant B-cell lymphoproliferative disorder, which still remains incurable. Reports on the latest research progress of WM were presented in the 58th American Society of Hematology (ASH) Annual Meeting, covering the theoretical and clinical researches of this disease. In basic research, mechanism of ibrutinib resistance has been further explored. The application of modern technologies, such as next-generation sequencing, has promoted the pathogenesis and prognosis of WM. In clinical research, retrospective analyses of traditional treatment provide new theoretical foundation in the choice of regimen, while clinical trials on new drugs including BGB-3111 and oprozomib may improve the therapy. The research advances in WM will be summarized in this paper.

Hodgkin lymphoma (HL) is a highly curable malignancy for most patients. Frontline treatment is generally ABVD alone or combination with other chemotherapy regimens or radiation. However, the treatment of relapsed refractory HL (RR HL) remains a major challenge for clinicians. High dose chemotherapy followed by autologous stem cell transplantation is the preferred treatment for chemoresistant patients. In addition, the combination of brentuximab vedotin (BV) with programmed cell death receptor 1 monoclonal antibody nivolumab, BV combined with ICE (ifosfamide, carboplatin, etoposide), panobinotast in combination with ICE and many other new drugs are in clinical trials and research. The latest progress in treatment of HL is reported in depth in the 58th American Society of Hematology Annual Meeting.

Marginal zone lymphoma (MZL) accounts for approximately 10 % of non-Hodgkin lymphoma (NHL). It can be divided into three specific entities:extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), nodal marginal zone lymphoma (NMZL) and splenic marginal zone lymphoma (SMZL). MALT lymphoma is the most frequent overall, representing 7.5 % of all NHLs. Reports on research progress of MZL in the 58th American Society of Hematology Annual Meeting covered multiple respects which ranged from basic research to clinical prognosis and treatment. Based on the technology such as flow cytometry, cytogenetics and FISH, further study on pathogenesis of MZL is developing, and new prognostic index system can help to stratify patients more exactly and give a guidance to treatment. What's more, the change of therapy and new drugs will benefit to the clinical efficacy and safety of MZL patients.

Follicular lymphoma (FL) is a kind of indolent non-Hodgkin lymphoma (iNHL), which origins from follicle germinal center. Multiple researches reported the latest development about treatment of FL in the 58th American Society of Hematology (ASH) Annual Meeting. The outcomes of clinical trials in which GAl01 combined with chemotherapy and bendamustine in combination with 90Y-ibritumomab tiuxetan for the advanced stage FL were exciting. Relapsed/refractory FL patients who receive tandem autologous followed by nonmyeloablative allogeneic transplantation could acquire preferable remissions. With the emerging of novel drugs including inhibitor of bcl-2 or PI3K and antibody drug conjugate, more and more improvements of efficacy and remission were made in the treatment of relapsed/refractory FL therapy and remission.

Objective:To investigate the possibility of producing vaccine with higher effect of anti-hepatoma by means of freezing the tumour cells which have been modified by TNF-? genes before. Methods: H22 cells which had been modified by TNF-? genes were treated by means of freezing and 60Co radiation or of 60Co radiation, respectively. Then, they were put to use to produce two kinds of vaccines. Effects of these two kinds of vaccines on anti- plant-hepatoma in mice were compared. Results: Effects of increasing the inhibiting rates, the levels of lectin-induced IL-2 and TNF from splenocytes, and the splentic NK activity, were all obviously seen stronger in vaccine made up of cells treated by the method combined with freezing, than that in vaccine made up of cells by no freezing. Conclusion: Method of freezing, after procedure of TNF-a gene modifying, could raise up the immunogenicity of the tumour cells, thereby enhance the anti-plant-hepatoma effect in mice induced by the vaccine.

Objective:To introduce the clinical application of the coil-spring utility arch for orthodontic treatment. Methods:A 35-year-old male patient with mild skeletal anterior crossbite was treated by fixed appliance combined with coil-spring utility arch for 16 months. Cephalometric analysis was conducted before and after treatment.Results:After treatment, the patient's appearance was improved,and the cephalometric analysis showed that SNA increased by 2?,SNB decreased by 1?,ANB increased by 3?,U1-NA increased by 1?,L1-NB increased by 3?.Conclusion:Coil-spring utility arch can expand anterior dental arch continuously and stably.

Objective:To evaluate the effects of different enamel conditioners in combination with an adhesive on the shear bond strength and the adhesive remnant index in vitro.Methods:One hundred and eight permanent healthy premolars from orthodontic patients and fresh saliva from a healthy young volunteer were collected.The teeth were cleaned,dried and etched by phosphoric acid,polyacrylic acid or Transbond plus SEP respectively(36 teeth for each agent).Then the teeth were bonded to brachet by RMGICs with the presence of water,saliva on the tooth surface or without any of them respectively(12 teeth in each group).After bonding,all samples were tested on a testing machine of Instron.Shear bond strength and adhesive remnant index were recorded.Results:Highest mean shear bond strength was observed in the group of teeth etched by Traspond plus SEP and bonded by RMGICs with the presence of saliva.Higher mean shear bond strength was obtained with the presence of saliva or water on the tooth surface than without any of them.Conclusion:Transbond plus SEP conditioning followed by RMGICs bonding may produce high shear bond strength between moistured tooth surface and brachet.